Recently, other have shown that by using an agonist 4-1BB antibody during the initialing of culture increased the numbers of memory CD8+ TIL that were specific for autologous tumor and represents a promising approach to increase the number of patients eligible to receive adoptive immunotherapy with TIL [39]. Here, CD8A is linked to neoplasm.